Northern Trust Corp Sells 365,760 Shares of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS)

Northern Trust Corp cut its position in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) by 74.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,938 shares of the company’s stock after selling 365,760 shares during the quarter. Northern Trust Corp owned about 0.19% of Xeris Pharmaceuticals worth $517,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in XERS. Kore Private Wealth LLC bought a new stake in shares of Xeris Pharmaceuticals during the 2nd quarter valued at $41,000. Principal Financial Group Inc. bought a new stake in shares of Xeris Pharmaceuticals during the 2nd quarter valued at $56,000. Marshall Wace North America L.P. bought a new stake in shares of Xeris Pharmaceuticals during the 1st quarter valued at $71,000. Algert Global LLC bought a new stake in shares of Xeris Pharmaceuticals during the 2nd quarter valued at $81,000. Finally, Advisor Group Holdings Inc. lifted its position in shares of Xeris Pharmaceuticals by 31.2% during the 2nd quarter. Advisor Group Holdings Inc. now owns 31,635 shares of the company’s stock valued at $129,000 after acquiring an additional 7,515 shares during the period. Institutional investors and hedge funds own 42.63% of the company’s stock.

Several analysts recently weighed in on XERS shares. Zacks Investment Research downgraded Xeris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 12th. SVB Leerink started coverage on Xeris Pharmaceuticals in a research report on Wednesday, November 17th. They set an “outperform” rating and a $6.00 price objective for the company. Finally, HC Wainwright upped their price objective on Xeris Pharmaceuticals from $4.00 to $4.25 and gave the stock a “buy” rating in a research report on Thursday, November 11th.

Shares of XERS opened at $2.09 on Wednesday. Xeris Pharmaceuticals, Inc. has a 12-month low of $1.77 and a 12-month high of $7.94. The stock has a 50-day moving average price of $2.25. The company has a current ratio of 3.34, a quick ratio of 3.73 and a debt-to-equity ratio of 4.40. The firm has a market cap of $138.98 million, a PE ratio of -1.38 and a beta of 1.76.

Xeris Pharmaceuticals (NASDAQ:XERS) last issued its earnings results on Tuesday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02). Xeris Pharmaceuticals had a negative return on equity of 382.91% and a negative net margin of 267.90%. During the same period last year, the firm posted ($0.35) earnings per share. As a group, equities analysts forecast that Xeris Pharmaceuticals, Inc. will post -1.34 earnings per share for the current fiscal year.

In other news, insider Paul R. Edick bought 20,000 shares of the stock in a transaction on Monday, November 15th. The stock was acquired at an average price of $2.28 per share, with a total value of $45,600.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.01% of the stock is owned by corporate insiders.

Xeris Pharmaceuticals Profile

Xeris Biopharma Holdings, Inc is a holding company. It offers a novel formulation technology to bring ready-to-use, liquid-stable injectable to patients to remove many associated treatment burdens. The company was founded on May 20, 2021 and is headquartered in Chicago, IL.

Featured Story: What is diluted earnings per share (Diluted EPS)?

Institutional Ownership by Quarter for Xeris Pharmaceuticals (NASDAQ:XERS)